Roche Announces $50 Billion Investment in U.S. Operations Over Next Five Years

April 22, Basel – Roche announced today that it will invest USD 50 billion in the United States over the next five years. These investments further strengthen Roche's presence in the U.S., with 13 manufacturing sites and 15 R&D sites across its pharmaceuticals and diagnostics divisions, and are expected to create more than 12,000 new jobs, including nearly 6,500 construction jobs, as well as new...And 1,000 jobs for expanding facilities. This is another MNC, after Eli Lilly, Johnson & Johnson, and Novartis, to expand investment in the United States. ($23 Billion! Novartis Plans to Increase R&D and Production Investment in the U.S. Over the Next 5 Years$55 Billion! Johnson & Johnson Announces Major Move!!!）

As part of this investment, Roche will add to its existing workforce of more than 25,000 employees across 24 sites in eight states in the U.S. The investment will include:

Expanded and upgraded its U.S. manufacturing and distribution capabilities for its innovative pharmaceuticals and diagnostic product portfolios in Kentucky, Indiana, New Jersey, Oregon, and California.

The Most Advanced Gene Therapy Manufacturing Facility in Pennsylvania

A new 900,000-square-foot manufacturing center to support Roche's expanding portfolio of next-generation weight-loss drugs (location to be determined).

A New Continuous Glucose Monitoring Manufacturing Plant in Indiana

A new research and development center located in Massachusetts conducts cutting-edge artificial intelligence (AI) research and serves as the hub for Roche's new cardiovascular, renal, and metabolic R&D efforts.

Roche has significantly expanded and upgraded its existing pharmaceuticals and diagnostics R&D centers in Arizona, Indiana, and California.

Roche CEO Thomas Schinecker stated:"Roche is a Swiss company with a strong tradition in over 130 countries worldwide. The investment announced today underscores our long-term commitment to R&D and manufacturing in the United States. We are proud of our 110-year history in the U.S., which has been a key driver of job creation, innovation, and intellectual property for our pharmaceuticals and diagnostics divisions. Our $50 billion investment over the next five years will lay the foundation for our next era of innovation and growth, benefiting patients in the United States and around the world."

Once all the new and expanded production capacity is online, Roche will export more pharmaceuticals from the United States than it imports. Currently, its diagnostics division already exports a surplus from the U.S. to other countries.

Although medicines are exempt from the latest round of tariffs,Trump's renewed threats around industry-specific tariffs on pharmaceuticals have led to a decline in sector stocks in recent days. Trump had previously suggested that drug tariffs could climb to "25% or higher."

As early as February, during an event named "Eli Lilly America," Eli Lilly announced a $27 billion investment to build four new U.S. production facilities, marking the largest allocation of funds for American manufacturing since 2020.More than twice as much. (Another $3 Billion Investment! Lilly Announces Expansion, GLP-1 Production Capacity Further Boosted）

Later, Johnson & Johnson stated that it would invest $55 billion in the United States over the next four years, including the expansion of three new manufacturing bases and other plants within the pharmaceutical giant’s drug and medical technology network. Johnson & Johnson's planned investment represents an increase over the previous four-year period.Increased by 25%.